Tokyo, Sept. 9 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058943) titled 'Effects of Heel-Elevated Standing and Walking Training on Parkinson's Disease Patients: Motion Analysis Using Artificial Intelligence' on Sept. 9.

Study Type: Interventional

Study Design: Basic Design - Single arm Randomization - Non-randomized Blinding - Open -no one is blinded Control - Uncontrolled

Primary Sponsor: Institute - Kochi University

Condition: Condition - Parkinson's disease Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - In this study, we will provide home exercise guidance to community-dwelling PD patients, utilizing heel lifts and visual cues for standing and walking practice aimed at improving gait. We will evaluate the effectiveness of this intervention. To assess changes in gait quality, we will record videos and analyze them using motion analysis software powered by artificial intelligence. Additionally, we will assess motor and cognitive function. This study aims to analyze the relationship between these assessment results and walking ability, investigating any characteristics or trends that emerge. Basic objectives2 - Safety,Efficacy

Intervention: Interventions/Control_1 - We provide indoor shoes with insoles to elevate the heel. Under these conditions, we instruct exercises that can be performed at home. The exercise regimen consists of: 1. Chair stand-up practice (Guideline: 5-10 repetitions for 2-3 sets, at a slightly challenging intensity), 2. Step practice using visual cues (Guideline: 20 steps left and right for 2-3 sets, at a slightly challenging intensity), 3. Walking practice using visual cues (Guideline: 3-5 round trips for 2-3 sets, at a slightly challenging intensity). Participants will perform these exercises for 2 weeks, after which effectiveness will be assessed. For those who wish, carryover effects will be evaluated. Participants will then resume their usual routine for 2 weeks, followed by a carryover effect assessment 2 weeks later. If medication dosage changes cause a noticeable change in the participant's usual condition, participation in the study may be discontinued. These exercises and evaluations are within the scope of standard medical care.

Eligibility: Age-lower limit - 20 years-old = Gender - Male and Female Key inclusion criteria - Parkinson's disease patients capable of safe independent walking Key exclusion criteria - Those unable to respond to the survey Target Size - 20

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2025 Year 08 Month 27 Day Date of IRB - 2025 Year 08 Month 28 Day Anticipated trial start date - 2025 Year 09 Month 14 Day Last follow-up date - 2026 Year 12 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067378

Disclaimer: Curated by HT Syndication.